Edwards Lifesciences AI Stock Analysis
Edwards Lifesciences (0REN) AI Stock Analysis
Edwards Lifesciences
(LSE:0REN)
No summary available
Edwards Lifesciences Business Overview & Revenue Model
Company Description
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United...
Edwards Lifesciences Earnings Call Summary
The call was strongly positive. Edwards reported better-than-expected third-quarter results, raised full-year sales, TAVR, TMTT and EPS guidance, highlighted broad clinical and regulatory progress, and expressed confidence in durable long-term growth. The main challenges were GAAP EPS impairment, foreign-exchange and tax headwinds, expected fourth-quarter margin phasing, moderating TAVR share gains and the gradual timing of new-indication benefits.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full-year 2026 total sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97 to $3.05, growing 18% at the midpoint versus prior year; fourth-quarter sales are projected at $1.67 billion to $1.75 billion with adjusted EPS of $0.61 to $0.69. Full-year TAVR guidance is 9% to 9.5%, with durable mid- to high single-digit growth over the long term; TMTT sales are expected to be between $780 million and $790 million, supporting a path to $2 billion in TMTT revenue in 2030; and Surgical guidance remains mid-single-digit sales growth. Adjusted gross margin is expected at the lower end of the full year 78% to 79% gross margin guidance, operating margin at the high end of the original 28% to 29% guidance with approximately 150 basis points of constant currency operating margin expansion, fourth-quarter operating margin in the mid-20s, R&D expense at approximately 16.5% of sales, effective tax rate at the high end of 16% to 19%, fourth-quarter FX headwind of approximately $15 million, and average diluted shares outstanding between 575 million and 580 million; beyond 2026, Edwards plans for 50 to 100 basis points of underlying operating margin expansion and approximately 10% average annual sales growth alongside leveraged EPS growth.
Edwards Lifesciences Risk Analysis
Edwards Lifesciences disclosed 28 risk factors in its most recent earnings report. Edwards Lifesciences reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksEdwards Lifesciences Peers Comparison
Overall Rating
MDT81Outperform
LIVN77Outperform
ABT67Neutral
PEN67Neutral
BSX64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $131.58B | 25.15 | 10.60% | 2.78% | 9.77% | 12.28% | |
| 77Outperform | $5.03B | 25.51 | 15.35% | ― | 11.71% | ― | |
| 67Neutral | $187.95B | 40.19 | 9.11% | 2.32% | 10.00% | -66.06% | |
| 67Neutral | $12.65B | 80.43 | 10.44% | ― | 16.98% | -5.62% | |
| 64Neutral | $64.27B | 18.71 | 13.87% | ― | 8.88% | 25.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ABT | Abbott Laboratories | 108.52 | -18.36 | -14.47% | |
| BSX | Boston Scientific | 44.34 | -57.42 | -56.43% | |
| MDT | Medtronic | 102.86 | 9.67 | 10.38% | |
| PEN | Penumbra Inc. | 320.91 | 42.40 | 15.22% | |
| LIVN | LivaNova PLC | 91.32 | 37.68 | 70.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
